Obesity rings in New Year with Lilly-Nimbus $1.3B deal, RNAi data

Biopharma industry zeal for obesity therapeutics does not appear to be dying down any time soon, with Eli Lilly and Co. entering a $1.3 billion deal with Nimbus Therapeutics LLC for a new small molecule, and Arrowhead Pharmaceuticals Inc. rolling out phase I/IIa data of its RNAi therapeutics used in combination with Lilly’s GLP-1/GIP receptor […]

GLP-1 Use Linked to Lower Colon Cancer Risk vs Aspirin

(MedPage Today) — SAN FRANCISCO — Patients with a history of GLP-1 receptor agonist treatment had a significantly lower risk of developing colorectal cancer (CRC) as compared with those who took aspirin, according to a retrospective study reported…

Drugmakers Fight Multifront Legal Battles Over GLP-1s

In the wake of U.S. Food and Drug Administration approvals for GLP-1 weight-loss drugs, surging public demand and massive profits have inspired a broad range of drugmaker litigation against competitors, alleged counterfeits and telehealth providers.

This week’s books in Medicine

Here are this week’s new releases for the category ‘Medicine’. ★ Our Staff Pick ★ Your Best Shot: The Personalized System for Optimal Weight Health―GLP-1 Shot or Not By Ashley Koff RD Publisher: HarperOne Publication date: January 6, 2026 ISBN: 9780063444188 Format: Hardcover Share this book on Twitter | Facebook Eat Your Ice Cream: Six […]